4.5 Review

Treatment of Human Babesiosis: Then and Now

Journal

PATHOGENS
Volume 10, Issue 9, Pages -

Publisher

MDPI
DOI: 10.3390/pathogens10091120

Keywords

babesiosis; Babesia microti; Babesia duncani; parasite; therapy; atovaquone; endochin-like quinolones (ELQs)

Categories

Funding

  1. NIH [AI-123321, AI-138139, AI-152220, AI-153100, AI136138]
  2. NIH (Steven & Alexandra Cohen Foundation)
  3. NIH (Global Lyme Alliance)

Ask authors/readers for more resources

Babesiosis is an emerging tick-borne disease caused by Babesia parasites, posing a growing public health concern due to increasing incidence and human-to-human transmission risk. Current treatment options are limited, associated with adverse events and drug resistance, highlighting the urgent need for new therapeutic strategies tailored to Babesia parasites.
Babesiosis is an emerging tick-borne disease caused by apicomplexan parasites of the genus Babesia. With its increasing incidence worldwide and the risk of human-to-human transmission through blood transfusion, babesiosis is becoming a rising public health concern. The current arsenal for the treatment of human babesiosis is limited and consists of combinations of atovaquone and azithromycin or clindamycin and quinine. These combination therapies were not designed based on biological criteria unique to Babesia parasites, but were rather repurposed based on their well-established efficacy against other apicomplexan parasites. However, these compounds are associated with mild or severe adverse events and a rapid emergence of drug resistance, thus highlighting the need for new therapeutic strategies that are specifically tailored to Babesia parasites. Herein, we review ongoing babesiosis therapeutic and management strategies and their limitations, and further review current efforts to develop new, effective, and safer therapies for the treatment of this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available